Marvell Technology (MRVL) Strengthens Leadership Team With Key Executive Promotions
Buy, Hold or Sell Marvell Technology? View our complete analysis and fair value estimate and you decide.
This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.
The recent executive promotions at Marvell Technology could play a positive role in shaping the company's growth narrative, especially in the AI and data center sectors. By enhancing leadership with experienced executives like Chris Koopmans and Sandeep Bharathi, Marvell might strengthen its strategic focus on AI technologies and custom silicon programs, potentially accelerating revenue and earnings growth. The 39% rise in stock price over the past quarter aligns with investor optimism, but the true test will be in delivery against these elevated expectations.
Over a five-year period, Marvell's total shareholder return, including dividends, was 108.22%. This performance contrasts with the more recent underperformance against both the US Semiconductor industry and the broader US market over the past year. Marvell's share appreciation suggests strong long-term value creation, but the company still faces challenges to match the market's pace.
The impacts of leadership changes could influence projected revenue and earnings positively, expecting to exceed AI sector targets, although potential risks remain due to heavy reliance on the data center market. Currently, with the stock trading at US$72.01, analysts set a consensus price target of approximately US$90.27, reflecting a price movement that suggests room for appreciation. Achieving this target requires confidence in Marvell's capacity to execute its growth strategies, underscoring the importance of the company's ongoing technological advancements and market positioning.
Click here and access our complete financial health analysis report to understand the dynamics of Marvell Technology.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MRVL.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
16 minutes ago
- Yahoo
Peter Lynch: You Shouldn't Own a Stock if You Can't Explain It to an 11-Year-Old in 2 Minutes
Famed investor Peter Lynch once underscored the significance of understanding the business behind a stock before investing in it, while also questioning the efficacy of economic forecasting. What Happened: Lynch, who is recognized for his successful stint at Fidelity Investments, disclosed his investment insights during a 1997 speech. He emphasized the importance of understanding the business behind the stock, advising, 'If you can't explain to an 11-year-old in two minutes or less, why you own the stock, you shouldn't own it. Understanding the business behind the stock is the most important principle of investing in the stock market. This is why Buffett only invests into what he understands and what falls in his circle of competence. I buy stuff like Dunkin Donuts, Stop and Shop and made money on them," Lynch said during the speech.' This philosophy is in line with Warren Buffett's investment strategy, which advocates for investing in areas of personal expertise. Lynch dismissed the concept of economic forecasting, identifying himself as a 'bottom-up' investor who concentrates on individual stocks through comprehensive company and industry analysis. Also Read: Investment Guru Peter Lynch: 'Often Great Investments Are The Ones Where Everyone Else Will Think You Are Crazy' He also underscored the significance of patience in investing, suggesting that substantial returns could be realized even a decade after a company's initial public offering. He cited Walmart as an example, stressing that investing is a marathon, not a sprint. 'A decade after Walmart when public in 1970, it only had 15% penetration across the U.S. Thus, one could assume they had plenty of runway ahead to expand across the country, but success wasn't guaranteed, so some investors might have though they already missed the bus,' Lynch said while talking about the Walmart. Why It Matters: Lynch's principles provide a valuable roadmap for both novice and seasoned investors. His emphasis on understanding the business, focusing on individual stocks, and practicing patience aligns with the strategies of successful investors like Buffett. His insights serve as a reminder to investors that successful investing hinges on making informed decisions and playing the long game. Read Next Peter Lynch's Market Advice: 'You Don't Need A Lot In Your Lifetime, You Only Need A Few Good Stocks In Your Lifetime' Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Peter Lynch: You Shouldn't Own a Stock if You Can't Explain It to an 11-Year-Old in 2 Minutes originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Ex-Treasury Secretary Calls Trump Worse Than Nixon After Jobs Report Tantrum
President Donald Trump's inability to face the facts is yet another sign he's tilting towards tyranny, according to one former White House Cabinet member. After the release of a weak July jobs report and dismal updates to May and June numbers on Friday, a furious Trump sacked the top official at the Bureau of Labor Statistics in a post on Truth Social. 'The Economy is BOOMING under 'TRUMP,'' he declared while accusing BLS Commissioner Dr. Erika McEntarfer and her agency of manipulating employment statistics 'for political purposes.' Following McEntarfer's unceremonious ouster, Larry Summers, the treasury secretary under former President Bill Clinton, warned that Trump's actions are a dire sign for democracy when he appeared on the Sunday episode of ABC's 'This Week.' 'This is way beyond anything that Richard Nixon ever did,' Summers told host George Stephanopoulos. It's 'preposterous' for Trump to accuse the Bureau of Labor Statistics of warping employment numbers for political gain, Summers said, explaining that jobs data is meticulously calculated by hundreds of experts following rigorous formulas. Alarmed that the president would act like the figures were anything but objective, Summers told Stephanopoulos, 'This is the stuff of democracies giving way to authoritarianism.' Offering several more examples of Trump's autocratic impulses, he added, 'Firing statisticians goes with threatening the heads of newspapers, it goes with launching assaults on universities, it goes with launching assaults on law firms that defend clients that the elected boss finds uncongenial. This is really scary stuff.' Trump's labor report tantrum follows his decision to sue Wall Street Journal reporters and the paper's owner, Rupert Murdoch, over reports detailing his alleged connections to convicted sex offender Jeffrey Epstein. He also appeared to strong-arm television giant Paramount into a $16 million settlement just as it was seeking federal approval for a major merger with Skydance Media. The president successfully threatened to strip billions in funding from universities to drop their diversity, equity and inclusion policies while also accusing the institutions of failing to address antisemitism on campus. Before that, Trump pressured nine of the nation's top legal outfits into providing a collective $1 billion in pro bono services to avoid retaliation for their connections to federal prosecutors who oversaw investigations related to his first impeachment and the criminal investigations into Trump supporters' Jan. 6, 2021, attack on the U.S. Capitol. To Summers, the legal free-for-all and the tumult of Trump's ongoing tariff announcements seem like a recipe for economic instability. 'Who knows what business is going to be attacked next? Who knows what the rules are going to be?' he said. 'In an environment like that, what should a business do? It should sit, and it should wait.' Related... Trump Fires Labor Statistics Head In Meltdown Over Grim Jobs Report Senate Heads Home With No Deal On Nominations As Irate Trump Tells Schumer 'Go To Hell' It's Trump's Economy Now — And The Latest Financial Numbers Offer Some Warning Signs
